Page last updated: 2024-08-24

topotecan and irinotecan

topotecan has been researched along with irinotecan in 222 studies

Research

Studies (222)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's71 (31.98)18.2507
2000's84 (37.84)29.6817
2010's57 (25.68)24.3611
2020's10 (4.50)2.80

Authors

AuthorsStudies
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL1
Beijnen, JH; de Jong, LA; Hausheer, FH; Maliepaard, M; Pluim, D; Schellens, JH; Tohgo, A; van Gastelen, MA; van Waardenburg, RC1
LaVoie, EJ; Li, TK; Liu, A; Liu, LF; Ruchelman, AL; Singh, SK1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC1
Che, X; Ji, H; Miao, Z; Shao, L; Sheng, C; Yao, J; You, L; Zhang, J; Zhang, M; Zhang, W1
Lombardo, F; Obach, RS; Waters, NJ1
Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, YL; Cheng, CM; Chung, KY; Tseng, CH; Tzeng, CC; Wang, CH1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Che, X; Cheng, P; Dong, G; Feng, H; Guo, W; Liu, W; Luo, C; Miao, Z; Sheng, C; Wang, J; Wang, W; Xu, Y; Yao, J; You, L; Zhang, J; Zhang, W; Zhou, L; Zhu, L1
Chen, X; Lin, X; Skolnik, S; Wang, J1
Ahluwalia, D; Bhupathi, D; Cai, X; Duan, JX; Hart, CP; Huang, H; Jiao, H; Jung, B; Jung, D; Liu, Q; Matteucci, J; Matteucci, M; Meng, F; Sun, JD1
Chen, YL; Cheng, CM; Chung, KY; Hsu, CY; Huang, KS; Kao, CL; Tseng, CH; Tzeng, CC1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y1
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Chen, S; Dong, G; Fang, K; Li, J; Liu, N; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL1
Benetti, E; Centamore, A; Collina, S; Della Volpe, S; Martino, E; Sakaj, M; Sala, A; Terribile, E1
Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX1
Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Song, ZL; Yang, CJ; Zhang, JX; Zhao, YL1
Goto, M; Hsu, PL; Lee, KH; Liu, YQ; Morris-Natschke, SL; Shang, XF; Song, ZL; Wang, MJ; Yang, CJ; Yang, QR; Zhang, XS1
Chen, Y; Gao, JM; Lee, KH; Li, B; Li, H; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wang, MJ; Xu, C; Yang, CJ; Zhang, ZJ; Zhao, XB1
Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G1
Ariyoshi, Y; Sugiura, T1
Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD1
Slichenmyer, WJ; Von Hoff, DD1
Bonneterre, J1
Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ1
Ettinger, DS1
Burke, TG; Malak, H; Mi, Z1
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L1
Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M1
Sinha, BK1
Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR1
Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F1
Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR1
Schellens, JH; Verweij, J1
Burris, HA; Fields, SM1
Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD1
Funk, LR; Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL; Polsky, RM1
Green, MR1
Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P1
Burke, TG; Mi, Z1
Creemers, GJ; Lund, B; Verweij, J1
Donehower, RC; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ1
Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L1
Furue, H1
Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A1
Donehower, RC; Slichenmyer, WJ1
Dancey, J; Eisenhauer, EA1
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D1
Mani, S; Ratain, MJ1
Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC1
Friedman, HS; Houghton, PJ1
Willson, JK1
Gutzler, F1
Burke, TG; Warner, DL1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A1
de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J1
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A1
Furuse, K1
Sugiyama, T; Ushijima, K; Yakushiji, M1
Rothenberg, ML1
Negoro, S1
Kaye, SB; Vasey, PA1
Ghaemmaghami, M; Jett, JR1
Astoul, C; Ollitrault, N; Salvat, D1
Boersma, AW; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J1
Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM1
Arbuck, SG; Kieffer, LV; Takimoto, CH1
Bunn, PA; Kelly, K1
Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G1
Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J1
McCann, J1
Punt, CJ1
Brown, R; McDonald, AC1
Beijnen, JH; Herben, VM; Schellens, JH; Ten Bokkel Huinink, WW1
de Jonge, MJ; Sparreboom, A; Verweij, J1
Arbuck, SG; Takimoto, CH1
Muggia, FM; O'Leary, J1
Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL1
Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E1
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC1
Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P1
Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD1
Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT1
Chen, AY; Choy, H; Rothenberg, ML1
Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C1
Blanke, CD; Rothenberg, ML1
Groshen, S; Keshelava, N; Reynolds, CP1
Boisdron-Celle, M; Boulanger, N; Gamelin, E1
Kelly, K2
Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P1
Arbuck, SG; Kieffer, LV; Kieffer, ME; Takimoto, CH; Wright, J1
Allegra, CJ; Grem, JL; Paull, K; Pommier, Y; Voeller, DM1
Rivory, LP; Robert, J1
de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J1
Sandler, A1
Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF1
Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW1
Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY1
Smart, T1
Lokich, J1
Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W1
Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW1
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S1
Berg, SL; Blaney, SM; Bomgaars, L1
Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G1
Cunha, KS; Graf, U; Reguly, ML; Rodrigues de Andrade, HH1
Kato, Y; Saijo, N1
Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T1
Houghton, PJ; Santana, VM1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH1
Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J1
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L1
Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T1
Sandler, AB1
Bailly, C; Lansiaux, A1
Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C1
Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y1
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL1
Soepenberg, O; Sparreboom, A; Verweij, J1
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Cheung, NK; Kramer, K; Kushner, BH; Modak, S2
Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K1
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P1
Hayakawa, Y1
Holcombe, RF; Kong, KM; Wimmer, D1
Cho, LC; Choy, H1
Beijnen, JH; Borst, P; Breedveld, P; Pluim, D; Schellens, JH; Schinkel, AH; Sönmezer, O; Tibben, MM; van Tellingen, O; Zelcer, N1
Yang, S; Zhang, WN1
Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K1
Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH1
Murphy, BA1
Seiter, K1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Fujita, F; Fujita, M; Fujiwara, T; Kakushima, M; Kawaguchi, T; Kiuchi, S; Koike, M; Kudoh, S; Okuno, S; Sakamoto, Y; Yano, S; Yano, T1
Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M1
Bourget, P; Gravel, E; Mercier, L; Paci, A1
Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C1
Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M1
LaVoie, EJ; Liu, AA; Liu, LF; Ruchelman, AL; Zhou, N; Zhu, S1
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H1
Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F1
Pujol, JL1
Fournel, P1
Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS1
Leu, YL; Prijovich, ZM; Roffler, SR1
Gupta, AA; Pappo, AS1
Cai, Y; Chen, Y; Ding, J; Gao, H; Huang, M; Jiang, H; Lin, L; Lu, W; Miao, Z; Shen, H; Zhang, J; Zhang, X; Zhu, H1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH1
Gounder, MK; Kulkarni, D; Nazar, AS; Pungaliya, P; Rubin, EH; Saleem, A; Versace, R1
Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC1
Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F1
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB1
Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT1
Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML1
Feun, L; Savaraj, N1
Herzog, TJ; Wethington, SL; Wright, JD1
Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ1
Srinivas, NR1
Al-Rejaie, SS; Al-Shabanah, OA; Al-Yahya, AA; Aleisa, AM; Ashour, AE; Attia, SM; Bakheet, SA1
Chen, GQ; Cheng, JK; Han, YH; Liao, SH; Wang, LS; Wang, XL; Xia, L; Zheng, Y1
Jiang, C; Jin, W; Li, M; Lou, L; Tang, W; You, T; Zheng, C1
Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H1
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P1
Antonijevic, MD; Forster, RE; Heaysman, CL; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Small, SA; Tang, Y1
Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM1
Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z1
Aucélio, RQ; da Cunha, AL; Marques, FF1
Gmeiner, WH; Pommier, Y; Reinhold, WC1
Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M1
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S1
Lansiaux, A; Pourquier, P1
Miller, G1
Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y1
Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M1
Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y1
Hui, C; McVey, M; South, A; Thomas, AM1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N1
Lin, B; Shao, L; Song, Z; Zhang, Y1
Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O1
Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J1
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP1
Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV1
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M1
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T1
Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P1
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T1
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM1
Arakawa, Y1
Gjerset, RA; Zhao, M1
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR1
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N1
Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK1
Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N1
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K1
Amaria, R; Ashkin, E; Bernatchez, C; Chen, Y; Davis, RE; Devi, S; Forget, MA; Haymaker, C; Heffernan, T; Hu, J; Huang, L; Hwu, P; Kalra, A; Liu, C; Malu, S; Mbofung, RM; McKenzie, JA; Muller, F; Peng, W; Pradeep, S; Roszik, J; Satani, N; Sood, A; Tieu, T; Williams, L; Xu, C; Zhang, M; Zorro Manrique, S1
Chen, Y; Cheng, JG; Liu, Y; Yu, HJ1
Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I1
Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X1
Nazha, B; Owonikoko, TK1
Pommier, Y; Thomas, A1
Bakhutashvili, I; Banovac, F; Esparza-Trujillo, JA; Henman, A; Karanian, JW; Krishnasamy, VP; Levy, EB; Lewis, AL; Mikhail, AS; Negussie, AH; Pritchard, WF; Tang, Y; Wakim, PG; Willis, SL; Wood, BJ; Woods, DL1
Blanc, E; Bouleftour, W; Forges, F; Guitton, J; Hugues, M; Macé, A; Macron, C; Menguy, S; Raymond, B; Simoëns, X; Tinquaut, F1
Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A1
Abdullah, H; Agrawal, S; Deng, M; Meeker, C; Sreekrishnanilayam, K; Vijayvergia, N; Yeung, HM1
Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1
Jiang, M; Wang, X; Wang, Y; Yao, L; Zhuang, Y1
Bartlett, MG; King, GM; Mensah, GAK; Roberts, AG; Schaefer, KG1

Reviews

69 review(s) available for topotecan and irinotecan

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The long story of camptothecin: From traditional medicine to drugs.
    Bioorganic & medicinal chemistry letters, 2017, 02-15, Volume: 27, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; DNA Topoisomerases, Type I; Humans; Medicine, Traditional; Neoplasms; Structure-Activity Relationship

2017
[DNA topoisomerase inhibitor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13

    Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan

1992
Clinical trials with the topoisomerase I inhibitors.
    Seminars in oncology, 1992, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1992
New natural products in cancer chemotherapy.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan

1990
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bulletin du cancer, 1995, Volume: 82, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting

1995
New drugs for treating small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan

1995
New chemotherapeutic agents in non-small-cell lung cancer.
    Seminars in oncology, 1993, Volume: 20, Issue:2

    Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

1993
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Drugs, 1995, Volume: 49, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

1995
New anticancer agents.
    Cancer chemotherapy and biological response modifiers, 1994, Volume: 15

    Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine

1994
DNA topoisomerase inhibitors.
    Cancer chemotherapy and biological response modifiers, 1994, Volume: 15

    Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

1994
New chemotherapeutic agents for non-small cell lung cancer.
    Chest, 1995, Volume: 107, Issue:6 Suppl

    Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine

1995
Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Hematology/oncology clinics of North America, 1994, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

1994
New directions for chemotherapy in non-small-cell lung cancer.
    Chest, 1993, Volume: 103, Issue:4 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

1993
Pharmacokinetics and early clinical studies of selected new drugs.
    Cancer surveys, 1993, Volume: 17

    Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan

1993
Topoisomerase I inhibitors: topotecan and irenotecan.
    Cancer treatment reviews, 1994, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1994
The current status of camptothecin analogues as antitumor agents.
    Journal of the National Cancer Institute, 1993, Feb-17, Volume: 85, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; DNA Topoisomerases, Type I; Forecasting; Humans; Irinotecan; Topotecan

1993
[Topoisomerase inhibitors developing in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan

1993
Recent clinical advances with camptothecin analogues.
    Cancer treatment and research, 1995, Volume: 78

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan

1995
Current perspectives on camptothecins in cancer treatment.
    British journal of cancer, 1996, Volume: 74, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1996
New anticancer agents in clinical development.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan

1995
Promising new agents in oncologic treatment.
    Current opinion in oncology, 1996, Volume: 8, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan

1996
Topoisomerase-I inhibitors in the management of colon cancer.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

1996
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    British journal of cancer, 1997, Volume: 76, Issue:7

    Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1997
[Lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine

1997
[Promising new drugs for gynecological cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan

1997
Topoisomerase I inhibitors: review and update.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9

    Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

1997
["State-of-the-art" chemotherapy for small-cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine

1997
New agents in the treatment of small cell lung cancer.
    Chest, 1998, Volume: 113, Issue:1 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

1998
DNA topoisomerase I inhibitors.
    Cancer chemotherapy and biological response modifiers, 1997, Volume: 17

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1997
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine

1998
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
    Biochimie, 1998, Volume: 80, Issue:3

    Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1998
New drugs in the treatment of colorectal carcinoma.
    Cancer, 1998, Aug-15, Volume: 83, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil

1998
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Pharmacy world & science : PWS, 1998, Volume: 20, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

1998
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
    Cancer treatment reviews, 1998, Volume: 24, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Paclitaxel; Topoisomerase I Inhibitors; Topotecan

1998
An overview of topoisomerase I-targeting agents.
    Seminars in hematology, 1998, Volume: 35, Issue:3 Suppl 4

    Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1998
Camptothecins: a review of their development and schedules of administration.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan

1998
DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan

1999
Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

1999
[Pharmacokinetic monitoring].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan

2000
New chemotherapy agents for small cell lung cancer.
    Chest, 2000, Volume: 117, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine

2000
DNA topoisomerase I poisons.
    Cancer chemotherapy and biological response modifiers, 1999, Volume: 18

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan

1999
[Pharmacology of camptothecin and its derivatives].
    Bulletin du cancer, 1995, Volume: 82, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Irinotecan; Mutation; Topotecan

1995
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
    Anti-cancer drugs, 2000, Volume: 11, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

2000
Extensive small-cell lung cancer: a treatment overview.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:7 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2000
Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Medical and pediatric oncology, 2000, Volume: 35, Issue:4

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2000
Treatment of extensive stage small cell lung cancer.
    Cancer treatment and research, 2001, Volume: 105

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2001
Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:7 Suppl 8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2001
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34 Suppl 4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine

2001
The development of camptothecin analogs in childhood cancers.
    The oncologist, 2001, Volume: 6, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2001
Quantitation of camptothecin and related compounds.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Nov-25, Volume: 764, Issue:1-2

    Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

2001
[Developed new agents for lung cancer].
    Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine

2002
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Current cancer drug targets, 2002, Volume: 2, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2002
Chemotherapy for small cell lung cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan

2003
Clinical studies of camptothecin and derivatives.
    The Alkaloids. Chemistry and biology, 2003, Volume: 60

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mutagens; Topotecan

2003
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:7 Suppl 4

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan

2004
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2004
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:1

    Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan

2005
Toxicity of the topoisomerase I inhibitors.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:1

    Topics: Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan

2005
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome

2006
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
    Future oncology (London, England), 2006, Volume: 2, Issue:5

    Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan

2006
Topoisomerase I inhibitors for the treatment of brain tumors.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan

2008
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan

2008
[Molecular determinants of response to topoisomerase I inhibitors].
    Bulletin du cancer, 2011, Volume: 98, Issue:11

    Topics: Camptothecin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

2011
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
    Breast cancer research and treatment, 2013, Volume: 138, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2013
Targeting Topoisomerase I in the Era of Precision Medicine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 11-15, Volume: 25, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; DNA Topoisomerases, Type I; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Topoisomerase I Inhibitors; Topotecan

2019
The design and discovery of topoisomerase I inhibitors as anticancer therapies.
    Expert opinion on drug discovery, 2022, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2022
The recent developments of camptothecin and its derivatives as potential anti-tumor agents.
    European journal of medicinal chemistry, 2023, Nov-15, Volume: 260

    Topics: Antineoplastic Agents; COVID-19; Drug Liberation; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan

2023

Trials

10 trial(s) available for topotecan and irinotecan

ArticleYear
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan

1994
Preclinical and phase I trials of topoisomerase I inhibitors.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl

    Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay

1994
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Blood, 1993, Mar-01, Volume: 81, Issue:5

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan

1993
Phase I clinical trial of weekly combined topotecan and irinotecan.
    American journal of clinical oncology, 2001, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2001
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting

2004
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome

2006
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan

2008
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

2014
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan

2016
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan

2018

Other Studies

143 other study(ies) available for topotecan and irinotecan

ArticleYear
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
    Journal of medicinal chemistry, 1991, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous

1991
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:4

    Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Survival; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Neoplasm Proteins; Tetrahydroisoquinolines; Tumor Cells, Cultured

2001
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
    Journal of medicinal chemistry, 2003, May-22, Volume: 46, Issue:11

    Topics: Amines; Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Naphthyridines; Nitro Compounds; Structure-Activity Relationship; Tumor Cells, Cultured

2003
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
    Bioorganic & medicinal chemistry, 2007, Jun-15, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2007
New homocamptothecins: synthesis, antitumor activity, and molecular modeling.
    Bioorganic & medicinal chemistry, 2008, Feb-01, Volume: 16, Issue:3

    Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Imaging, Three-Dimensional; Imines; Methylation; Models, Molecular; Molecular Structure; Protein Binding; Pyridines; Quantitative Structure-Activity Relationship; Solubility; Water

2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.
    Bioorganic & medicinal chemistry, 2008, Sep-15, Volume: 16, Issue:18

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives.
    Bioorganic & medicinal chemistry, 2009, Nov-01, Volume: 17, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Drug Screening Assays, Antitumor; G2 Phase; Humans; Indenes; Poly(ADP-ribose) Polymerases; Quinolines; Tubulin

2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.
    Bioorganic & medicinal chemistry, 2010, May-01, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Esters; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Molecular Structure; Pharmaceutical Solutions; Phosphates; Structure-Activity Relationship

2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity

2011
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
    Journal of medicinal chemistry, 2011, Mar-24, Volume: 54, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Brain; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous

2011
Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives.
    Bioorganic & medicinal chemistry, 2011, Dec-15, Volume: 19, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; G1 Phase; Humans; Neoplasms; Quinolines

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
    Journal of medicinal chemistry, 2012, Sep-13, Volume: 55, Issue:17

    Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship

2012
Camptothecins in tumor homing via an RGD sequence mimetic.
    Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats

2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents.
    Journal of medicinal chemistry, 2015, Aug-27, Volume: 58, Issue:16

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Cycle; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Evodia; Humans; Models, Molecular; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators

2015
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
    European journal of medicinal chemistry, 2017, Jan-05, Volume: 125

    Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil

2017
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
    Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones

2017
Design, synthesis, and cytotoxic activity of novel 7-substituted camptothecin derivatives incorporating piperazinyl-sulfonylamidine moieties.
    Bioorganic & medicinal chemistry letters, 2017, 09-01, Volume: 27, Issue:17

    Topics: Amidines; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperazine; Piperazines; Structure-Activity Relationship

2017
Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives.
    Bioorganic & medicinal chemistry letters, 2017, 10-15, Volume: 27, Issue:20

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorine; Humans; Structure-Activity Relationship; Topotecan

2017
Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
    European journal of medicinal chemistry, 2020, Feb-01, Volume: 187

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Urea

2020
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
    European journal of medicinal chemistry, 2022, Nov-05, Volume: 241

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma

2022
Reduced albumin binding promotes the stability and activity of topotecan in human blood.
    Biochemistry, 1995, Oct-24, Volume: 34, Issue:42

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; DNA, Neoplasm; Drug Stability; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescence Polarization; HL-60 Cells; Humans; Irinotecan; Lactones; Molecular Structure; Serum Albumin; Topoisomerase I Inhibitors; Topotecan

1995
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1995
Topoisomerase I inhibition: a new target or new missiles?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan

1995
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.
    Oncology research, 1993, Volume: 5, Issue:12

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; DNA Damage; Drug Resistance; Female; Irinotecan; Leukemia P388; Mice; Topotecan

1993
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
    Journal of medicinal chemistry, 1994, Jan-07, Volume: 37, Issue:1

    Topics: Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Half-Life; Irinotecan; Kinetics; Lactones; Molecular Structure; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Topotecan

1994
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
    Cancer research, 1993, Jun-15, Volume: 53, Issue:12

    Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine

1993
Schedule-dependent efficacy of camptothecins in models of human cancer.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

1996
Treatment of central nervous system xenografts with camptothecins.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous

1996
[New drugs. Topoisomerase inhibitors].
    Zentralblatt fur Gynakologie, 1996, Volume: 118, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1996
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
    Journal of chromatography. B, Biomedical sciences and applications, 1997, Mar-28, Volume: 691, Issue:1

    Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan

1997
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water

1997
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1997
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
    British journal of cancer, 1997, Volume: 76, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

1997
[Derivatives of camptothecin. A new class of antineoplastic agents].
    Soins; la revue de reference infirmiere, 1997, Issue:621

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan

1997
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Irinotecan; Topotecan; Tumor Cells, Cultured

1998
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:12

    Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous

1997
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
    British journal of cancer, 1998, Volume: 77, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan

1998
Colon cancer: new drug options improve on 5-FU.
    Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1998
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    British journal of cancer, 1998, Volume: 78, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53

1998
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine

1999
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1999
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
    Cancer research, 1999, Sep-15, Volume: 59, Issue:18

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured

1999
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
    International journal of oncology, 1999, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

1999
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
    Anti-cancer drugs, 1999, Volume: 10, Issue:7

    Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured

1999
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Cancer research, 1999, Oct-01, Volume: 59, Issue:19

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

1999
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Cancer research, 1999, Dec-01, Volume: 59, Issue:23

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured

1999
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured

2000
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Phosphorylation; Thymidine Kinase; Thymidylate Synthase; Time Factors; Topotecan; Tumor Cells, Cultured; Zidovudine

2000
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:16

    Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured

2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2000
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Cancer research, 2001, Jan-15, Volume: 61, Issue:2

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay

2001
PML and a tale of two drug companies.
    Notes from the underground (New York, N.Y.), 1995,Winter, Issue:no 29

    Topics: AIDS-Related Opportunistic Infections; Albendazole; Blood-Brain Barrier; Camptothecin; Drug Industry; Humans; Irinotecan; JC Virus; Leukoencephalopathy, Progressive Multifocal; Microsporidiosis; Polymerase Chain Reaction; Topotecan

1995
Making inroads on PML.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Camptothecin; HIV Protease Inhibitors; Humans; Irinotecan; Leukoencephalopathy, Progressive Multifocal; Topotecan

1996
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
    Cancer research, 2001, Sep-15, Volume: 61, Issue:18

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus

2001
Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.
    Mutagenesis, 2002, Volume: 17, Issue:2

    Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Damage; Drosophila melanogaster; Enzyme Inhibitors; Female; Irinotecan; Male; Mutagenicity Tests; Mutation; Recombination, Genetic; Topoisomerase I Inhibitors; Topotecan; Wings, Animal

2002
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection

2002
Clinical trials using irinotecan.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays

2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    International journal of cancer, 2002, Jul-01, Volume: 100, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

2002
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:8

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan

2002
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:8

    Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured

2002
[A symphony for the camptothecins].
    Bulletin du cancer, 2003, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan

2003
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
    European journal of pharmacology, 2003, Jul-25, Volume: 473, Issue:2-3

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan

2003
Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan

2003
Apoptotic pathways of epothilone BMS 310705.
    Gynecologic oncology, 2003, Volume: 91, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured

2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
    British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured

2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    International journal of cancer, 2004, Jan-01, Volume: 108, Issue:1

    Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 1

    Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan

2004
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
    Cancer research, 2004, Feb-15, Volume: 64, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan

2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
    Cancer research, 2004, Apr-01, Volume: 64, Issue:7

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan

2004
[Structure-activity relationship analysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine

2004
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Cancer research, 2004, Aug-15, Volume: 64, Issue:16

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Baculoviridae; Benzimidazoles; Biological Transport; Camptothecin; Cell Line; DNA, Complementary; Dogs; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Membrane Transport Proteins; Methotrexate; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Omeprazole; Pantoprazole; Spodoptera; Sulfoxides; Topotecan; Transfection

2004
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan

2004
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Cancer research, 2004, Dec-15, Volume: 64, Issue:24

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha

2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Body Weight; Camptothecin; Cell Line, Tumor; Dextrans; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Time Factors; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays

2005
Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
    Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4

    Topics: Antineoplastic Agents; Calibration; Camptothecin; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Densitometry; Drug Industry; Drug Stability; Irinotecan; Models, Chemical; Pharmaceutical Preparations; Quality Control; Reproducibility of Results; Spectrometry, Fluorescence; Technology, Pharmaceutical; Topotecan

2005
Cancer cell adaptation to chemotherapy.
    BMC cancer, 2005, Jul-18, Volume: 5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation

2005
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
    Biochemical pharmacology, 2005, Oct-15, Volume: 70, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan

2005
Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.
    Bioorganic & medicinal chemistry, 2005, Dec-15, Volume: 13, Issue:24

    Topics: Amides; Camptothecin; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Esters; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Topoisomerase I Inhibitors; Topotecan

2005
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan

2006
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases

2006
[Is small cell lung cancer an orphan disease?].
    Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1

    Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine

2006
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
    Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1

    Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan

2006
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA Fragmentation; Dose-Response Relationship, Drug; Glucuronidase; Glucuronides; Humans; Hybridomas; Hydrogen-Ion Concentration; Hydrolysis; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Lactones; Molecular Structure; Prodrugs; Serum Albumin; Thymidine; Time Factors; Topotecan; Tritium

2007
Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; HL-60 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Topotecan

2007
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan

2008
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
    Investigational new drugs, 2008, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dogs; Drug Resistance, Neoplasm; Gene Expression; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Topotecan; Transfection

2008
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan

2007
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
    The EMBO journal, 2007, Nov-14, Volume: 26, Issue:22

    Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan

2007
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
    Current medical research and opinion, 2008, Volume: 24, Issue:4

    Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine

2008
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan

2008
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays

2008
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?
    Biomedical chromatography : BMC, 2009, Volume: 23, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mice; Myocardium; Tandem Mass Spectrometry; Topotecan

2009
Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.
    Environmental and molecular mutagenesis, 2009, Volume: 50, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cytogenetics; DNA Probes; DNA, Satellite; In Situ Hybridization, Fluorescence; Injections, Intraperitoneal; Irinotecan; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Topotecan

2009
NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.
    Proteomics, 2009, Volume: 9, Issue:8

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Down-Regulation; Doxorubicin; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Protein Kinase C-delta; RNA, Small Interfering; Topotecan; Transcription, Genetic; U937 Cells

2009
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
    Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Irinotecan; Models, Chemical; Rhodamines; Structure-Activity Relationship; Topotecan

2009
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays

2010
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:4

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays

2010
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.
    Journal of materials science. Materials in medicine, 2010, Volume: 21, Issue:9

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Pancreatic Neoplasms; Topotecan

2010
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
    Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan

2010
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
    The Journal of surgical research, 2011, Volume: 171, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays

2011
Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.
    Talanta, 2010, Nov-15, Volume: 83, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorescence; Irinotecan; Lasers; Pharmaceutical Preparations; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Topotecan

2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
    Pediatric blood & cancer, 2011, Volume: 56, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome

2011
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:12

    Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States

2010
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
    Brain tumor pathology, 2011, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine

2011
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
    European journal of pharmacology, 2011, Nov-16, Volume: 670, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan

2011
Neurodevelopmental disorders. New hope for a devastating neurological disorder.
    Science (New York, N.Y.), 2011, Dec-23, Volume: 334, Issue:6063

    Topics: Angelman Syndrome; Animals; Brain; Camptothecin; Drug Evaluation, Preclinical; Gene Expression Regulation; Genetic Therapy; Humans; Irinotecan; Mice; Neurons; Topotecan; Transcriptional Activation; Ubiquitin-Protein Ligases

2011
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.
    Anti-cancer drugs, 2012, Volume: 23, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays

2012
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Oncology reports, 2012, Volume: 27, Issue:6

    Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin

2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan

2012
Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.
    G3 (Bethesda, Md.), 2013, Volume: 3, Issue:1

    Topics: Animals; BRCA2 Protein; Camptothecin; Cytochrome P-450 Enzyme System; DNA Damage; DNA Primers; DNA Repair; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Genetic Complementation Test; Insect Proteins; Irinotecan; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan

2013
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome

2015
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan

2013
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8

    Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan

2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan

2013
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-15, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays

2014
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
    Molecules (Basel, Switzerland), 2014, Feb-17, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan

2014
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Angiogenesis, 2014, Volume: 17, Issue:3

    Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome

2014
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured

2014
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Cancer research, 2014, Dec-01, Volume: 74, Issue:23

    Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan

2014
[DNA topoisomerase I--targeting drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan

2015
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan

2015
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
    Molecular pharmaceutics, 2016, Apr-04, Volume: 13, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan

2016
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
    Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3

    Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53

2017
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Anti-cancer drugs, 2017, Volume: 28, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays

2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
    Journal of the National Cancer Institute, 2018, 07-01, Volume: 110, Issue:7

    Topics: Animals; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunotherapy, Adoptive; Irinotecan; Lymphocytes, Tumor-Infiltrating; Melanoma; Mice; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays

2018
Selective binding and controlled release of anticancer drugs by polyanionic cyclodextrins.
    Bioorganic & medicinal chemistry, 2018, 05-15, Volume: 26, Issue:9

    Topics: Acetates; Antineoplastic Agents; Cyclodextrins; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Liberation; Hydrogen-Ion Concentration; Irinotecan; Propionates; Topotecan

2018
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Journal of immunology research, 2018, Volume: 2018

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53

2018
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs.
    Chemical communications (Cambridge, England), 2018, Aug-21, Volume: 54, Issue:68

    Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan

2018
The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer, 2019, 04-01, Volume: 125, Issue:7

    Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan

2019
Safety and Tolerability of Topotecan-Eluting Radiopaque Microspheres for Hepatic Chemoembolization in a Rabbit Preclinical Model.
    Cardiovascular and interventional radiology, 2020, Volume: 43, Issue:12

    Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Irinotecan; Liver Neoplasms; Liver Neoplasms, Experimental; Microspheres; Rabbits; Topoisomerase I Inhibitors; Topotecan

2020
Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1.
    International archives of occupational and environmental health, 2021, Volume: 94, Issue:6

    Topics: Antineoplastic Agents; Cyclophosphamide; Gloves, Protective; Humans; Infusions, Intravenous; Irinotecan; Nurses; Occupational Exposure; Pemetrexed; Topotecan

2021
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
    Molecular cancer therapeutics, 2021, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
    Journal of gastrointestinal cancer, 2023, Volume: 54, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Male; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2023
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022
Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs.
    International journal of molecular sciences, 2023, Nov-07, Volume: 24, Issue:22

    Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Irinotecan; Protein Conformation; Topotecan

2023